Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL616209 | 1.00 | PTGS1 (0.30) | PTGS1TRPV1 | |
| SCHEMBL14771565 | 0.91 | PTGS1 (0.30) | PTGS1TRPV1 | |
| SCHEMBL614149 | 0.84 | — | — | |
| SCHEMBL19059648 | 0.80 | — | — | |
| SCHEMBL615848 | 0.80 | ADRB1 (0.43) | — | |
| SCHEMBL14771566 | 0.79 | KDM4E (0.30) | — | |
| SCHEMBL5202367 | 0.79 | PPARG (0.32) | — | |
| SCHEMBL19020058 | 0.78 | — | — | |
| SCHEMBL614538 | 0.77 | — | — | |
| SCHEMBL616795 | 0.77 | ADRB1 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106187942-B | Benzothiazolone compounds | 诺华股份有限公司 | 2020-06-26 | — | — | CN | disclosed |
| US-10251868-B2 | Benzothiazolone compound | NOVARTIS AG (CH) | 2019-04-09 | — | — | US | disclosed |
| US-10251868-B2 | Benzothiazolone compound | NOVARTIS AG (CH) | 2019-04-09 | — | — | US | disclosed |
| US-20180140582-A1 | BENZOTHIAZOLONE COMPOUND | NOVARTIS AG (CH) | 2018-05-24 | — | — | US | disclosed |
| US-20180140582-A1 | BENZOTHIAZOLONE COMPOUND | NOVARTIS AG (CH) | 2018-05-24 | — | — | US | disclosed |
| US-20180140582-A1 | BENZOTHIAZOLONE COMPOUND | NOVARTIS AG (CH) | 2018-05-24 | — | — | US | disclosed |
| US-9913828-B2 | Benzothiazolone compound | NOVARTIS AG (CH) | 2018-03-13 | — | — | US | disclosed |
| US-9913828-B2 | Benzothiazolone compound | NOVARTIS AG (CH) | 2018-03-13 | — | — | US | disclosed |
| US-9913828-B2 | Benzothiazolone compound | NOVARTIS AG (CH) | 2018-03-13 | — | — | US | disclosed |
| EP-3243817-A1 | SALTS OF BENZOTHIAZOLONE COMPOUND AS BETA-2-ADRENOCEPTOR AGONIST | Novartis AG (CH) | 2017-11-15 | — | — | EP | disclosed |
| US-20130245080-A1 | BENZOTHIAZOLONE COMPOUND | NOVARTIS AG (CH) | 2013-09-19 | — | — | US | disclosed |
| US-20130245080-A1 | BENZOTHIAZOLONE COMPOUND | NOVARTIS AG (CH) | 2013-09-19 | — | — | US | disclosed |
| WO-2013035047-A1 | BENZOTHIAZOLONE COMPOUND | NOVARTIS AG (CH) | 2013-03-14 | — | — | WO | disclosed |
| US-20120041041-A1 | 5-HYDROXY-BENZOTHIAZOLE DERIVATIVES HAVING BETA-2-ADRENORECEPTOR AGONIST ACTIVITY | NOVARTIS AG | 2012-02-16 | — | — | US | disclosed |
| US-8076489-B2 | 3H-benzothiazol-2-one derivatives, for example, (R)-7-[2-(1,1-dimethyl-2-phenyl-ethylamino)-1-hydroxy-ethyl]-5-hydroxy-3H-benzothiazol-2-one; useful for treating conditions that are prevented or alleviated by activation of the beta 2-adrenoreceptor | NOVARTIS AG (CH) | 2011-12-13 | — | — | US | disclosed |
| EP-1819686-B1 | 5-HYDROXY-BENZOTHIAZOLE DERIVATIVES HAVING BETA-2-ADRENORECPTOR AGONIST ACTIVITY | NOVARTIS AG (CH) | 2011-08-17 | — | — | EP | disclosed |
| EP-2305659-A1 | 5-hydroxy-benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | Novartis AG (CH) | 2011-04-06 | — | — | EP | disclosed |
| US-20080096940-A1 | 5-Hydroxy-Benzothiazole Derivatives Having Beta-2-Adrenoreceptor Agonist Activity | NOVARTIS AG (CH) | 2008-04-24 | — | — | US | disclosed |
| EP-1819686-A1 | 5-HYDROXY-BENZOTHIAZOLE DERIVATIVES HAVING BETA-2-ADRENORECPTOR AGONIST ACTIVITY | Novartis AG (CH) | 2007-08-22 | — | — | EP | disclosed |
| WO-2006056471-A1 | 5-HYDROXY-BENZOTHIAZOLE DERIVATIVES HAVING BETA-2-ADRENORECPTOR AGONIST ACTIVITY | NOVARTIS AG (CH) | 2006-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245080-A1 | BENZOTHIAZOLONE COMPOUND | SLC5A1, SLC10A1, REN | PTGS1 464/4885TRPV1 363/4885 |
| US-10251868-B2 | Benzothiazolone compound | SLC5A1, SLC10A1, REN | PTGS1 464/4885TRPV1 363/4885 |
| US-20180140582-A1 | BENZOTHIAZOLONE COMPOUND | SLC5A1, SLC10A1, REN | PTGS1 464/4885TRPV1 363/4885 |
| US-20120041041-A1 | 5-HYDROXY-BENZOTHIAZOLE DERIVATIVES HAVING BETA-2-ADRENORECEPTOR AGONIST ACTIVITY | ADRB2, ADRB1, ADRA2C | PTGS1 502/4885TRPV1 48/4885 |
| US-20080096940-A1 | 5-Hydroxy-Benzothiazole Derivatives Having Beta-2-Adrenoreceptor Agonist Activity | ADRB2, ADRB1, ADRA2C | PTGS1 502/4885TRPV1 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.